A key scientific panel of the US Food and Drug Administration has unanimously voted to recommend approval for Moderna’s (Nasdaq: MRNA) COVID-19 vaccine in the age group six to 17.
The US FDA will now decide whether to approve the jab for this age group, and while the agency is not bound by the committee’s vote, it normally goes the same way.
Approval for Moderna would enable the firm to catch up with rival Pfizer (NYSE: PFE), which has had approval for its jab in this age range for some time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze